After featuring the Global Giants in our first edition of Recurring Revenue Innovators, we now turn our attention to the Emerging Leaders—businesses with terrific potential to break out into commercial success with a new revenue model. From subscriptions to usage to tiered and freemium models, these companies are offering products and services on terms that are irresistibleto their customers.
What if we stopped arguing over which analytics software is best, and decided instead to use them all? With today’s analytics technologies, the conversation about open analytics and commercial analytics is no longer an either/or discussion. You can now combine the benefits of SAS and open source analytics within your organization. Download this e-book to learn how businesses in multiple industries are integrating disparate code and information to deploy models and deliver critical results with analytics.
Published By: DocuSign
Published Date: Apr 24, 2018
Life science companies are experiencing a significant transformation in how they bring new products to market.
Organizations must adapt to changes in the marketplace, such as global product commercialization, specialized medicine, new regulations, new payment models, and new technology that are driving more product variety, smaller drug volumes, and shorter product life cycles.
To meet the needs of this new commercial model, life science companies must re-envision the global supply chain and evolve the tools they use to run their business. The supply chain that was designed for launching blockbuster products will not work in the future.
Today, the global supply chain relies on a manual, paper-based process centered on printing documents and sending them via overnight mail, fax, or e-mail with scanned attachments. This time-consuming and costly process is errorprone, tedious for customers and team members, and vulnerable to security and compliance risks.